CareLit Fachartikel

A regulatory BCL2 promoter polymorphism (-938C>A) is associated with outcome in neuroblastoma

B Brockmeyer, H Bachmann, A Künkele, W Siffert, A Eggert, A Schramm, J Schulte, K Pajtler · Klinische Pädiatrie · 2010 · Heft 05

Dokument
1169228
CareLit-ID
Jahr
2010
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Klinische Pädiatrie
Autor:innen
B Brockmeyer, H Bachmann, A Künkele, W Siffert, A Eggert, A Schramm, J Schulte, K Pajtler
Ausgabe
Heft 05 / 2010
Seiten
–
Erschienen: 2010-05-07 00:00:00
ISSN
0300-8630
DOI
10.1055/s-0030-1254469

Zusammenfassung

Expression of the BCL-2 anti-apoptotic protein correlates with adverse outcome of neuroblastoma and confers chemoresistance to neuroblastoma cells. BCL2, therefore, serves as a bona fide drug target in neuroblastoma. With the development of BCL-2 inhibitors, a new therapeutic option is now available for evaluation. We hypothesized that a regulatory BCL2–938C>A promoter polymorphism, which significantly affects promoter activity and BCL-2 expression in different malignancies, may influence survival of neuroblastoma patients. We analyzed genotypes of the -938C>A BCL2 promotor SNP in a cohort of 174 patients with n…

Schlagworte

Neuroblastoma Patients Promoter Polymorphism Bcl-2 Survival Genotype Regulatory Outcome Expression Amplification Analysis Klinische Pädiatrie